Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacture, and wholesale of active pharmaceutical ingredients (APIs) in Taiwan and the United States. It offers API products, which include immunosuppressant, oncology, cardiovascular, and other products, as well as peptide drugs. The company also develops bulk pharmaceutical products, such as anti-anxiety agents, antidiabetics, laxatives, antifungals, antihistamines, antiseptics, antiulcerants, cardiovascular drugs, skeletal, muscle relaxants, hypolipaemics, antineoplastic, antihyperlipedemias, and immunosuppressant products, as well as provides research and development, and contract manufacturing services to new drug developers and generic drug companies. The company was formerly known as China Chemical Synthesis Industry Co., Ltd. Chunghwa Chemical Synthesis & Biotech Co., Ltd. was founded in 1964 and is headquartered in New Taipei City, Taiwan.
Chunghwa Chemical Synthesis & Biotech Dividend Announcement
• Chunghwa Chemical Synthesis & Biotech announced a annually dividend of NT$0.80 per ordinary share which will be made payable on 2024-08-19. Ex dividend date: 2024-07-26
• Chunghwa Chemical Synthesis & Biotech annual dividend for 2024 was NT$0.80
• Chunghwa Chemical Synthesis & Biotech annual dividend for 2023 was NT$1.30
• Chunghwa Chemical Synthesis & Biotech's trailing twelve-month (TTM) dividend yield is 2.08%
• Chunghwa Chemical Synthesis & Biotech's dividend growth over the last five years (2018-2023) was 21.06% year
• Chunghwa Chemical Synthesis & Biotech's dividend growth over the last ten years (2013-2023) was -1.42% year
Chunghwa Chemical Synthesis & Biotech Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-07-26 | NT$0.80 | annually | 2024-08-19 |
2023-07-24 | NT$1.30 | annually | 2023-08-18 |
2022-07-22 | NT$1.30 | annually | 2022-08-18 |
2021-07-22 | NT$1.50 | annually | 2021-08-18 |
2020-07-23 | NT$0.80 | annually | 2020-08-14 |
2019-07-24 | NT$1.20 | annually | 2019-08-15 |
2018-07-24 | NT$0.50 | annually | 2018-08-15 |
2017-07-24 | NT$0.50 | annually | 2017-08-15 |
2016-07-22 | NT$1.50 | annually | |
2015-07-23 | NT$0.50 | annually | |
2014-07-28 | NT$1.00 | annually | |
2013-07-18 | NT$1.50 | annually |
Chunghwa Chemical Synthesis & Biotech Dividend per year
Chunghwa Chemical Synthesis & Biotech Dividend growth
Chunghwa Chemical Synthesis & Biotech Dividend Yield
Chunghwa Chemical Synthesis & Biotech current trailing twelve-month (TTM) dividend yield is 2.08%. Interested in purchasing Chunghwa Chemical Synthesis & Biotech stock? Use our calculator to estimate your expected dividend yield:
Chunghwa Chemical Synthesis & Biotech Financial Ratios
Chunghwa Chemical Synthesis & Biotech Dividend FAQ
Other factors to consider when evaluating Chunghwa Chemical Synthesis & Biotech as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Chunghwa Chemical Synthesis & Biotech stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Chunghwa Chemical Synthesis & Biotech's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Chunghwa Chemical Synthesis & Biotech publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Chunghwa Chemical Synthesis & Biotech distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Chunghwa Chemical Synthesis & Biotech are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Chunghwa Chemical Synthesis & Biotech sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Chunghwa Chemical Synthesis & Biotech distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Chunghwa Chemical Synthesis & Biotech declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Chunghwa Chemical Synthesis & Biotech's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Chunghwa Chemical Synthesis & Biotech's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.